HOWL News and Press, Werewolf Therapeutics Inc. From 08/11/22

Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q2 GAAP EPS of -$0.53 misses by $0.11 . Revenue of $4.15M. As of June 30, 2022, cash and cash equivalents were $145.7 million, compared to $157.5 million as of December 31, 2021. For further details s...

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for WTX-330 planned in 2H22 - - Q2 cash and cash equivalents balance of $145.7 million provides runway through at least the fo...

WATERTOWN, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bo...

Jazz Pharmaceuticals missed first quarter revenue estimates, but management raised the full-year guidance. The launch of Xywav in idiopathic hypersomnia looks strong, and has driven the best quarter for the oxybate franchise since mid-2020. Business development activity picked up ...

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bo...

Werewolf Therapeutics (NASDAQ:HOWL) stock rose ~7% June 2 after H.C. Wainwright assumes coverage of the company with a Buy rating and $20 price target. Analyst Andres Maldonado noted that Werewolf's Predator protein engineering technology aims to mimic natural cytokine activity while imp...

Werewolf Therapeutics press release (NASDAQ:HOWL): Q1 GAAP EPS of -$0.56 beats by $0.05. The company expects that its existing cash and cash equivalents of $143.7M, together with the upfront payment from the Jazz agreement as well as access to the $20M first tranche of its term loan agreement...

- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront payment and eligibility for up to $1.26B in downstream milestones as well as royalties on potential future sales - - Presented p...

WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated significant expansion of the therapeutic window, compared to recombinant IL-12, and generated potent anti-tumor immunity in ...

Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...